Search Result
Results for "
Erythromycin
" in MedChemExpress (MCE) Product Catalog:
5
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-B0220
-
Erythromycin
Maximum Cited Publications
18 Publications Verification
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-N7121
-
|
Bacterial
|
Infection
|
Erythromycin estolate, erythromycin derivative , is a macrolide antibiotic used in the treatment of a wide variety of bacterial infections. Erythromycin estolate causes several cases of liver injury which mostly include cholestatic hepatitis. Erythromycin estolate toxicity is related to its inhibitory effect on bile acid transport .
|
-
-
- HY-B0957
-
Erythromycin ethyl succinate; EES
|
Bacterial
HIV
Autophagy
Antibiotic
|
Infection
|
Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
|
-
-
- HY-100584
-
Erythromycin Cyclocarbonate
|
Bacterial
Antibiotic
|
Infection
|
Davercin (Erythromycin Cyclocarbonate), derivative of Erythromycin, which is active against Gram-positive and some Gram-negative microorganisms.
|
-
-
- HY-B0220H
-
|
Bacterial
Others
Antibiotic
DNA/RNA Synthesis
|
Infection
|
Erythromycin hydrochloride is a protein synthesis inhibitor with activity against the growth of both Gram-negative and Gram-positive bacteria. Erythromycin hydrochloride is commonly used in biomedicine to inhibit diseases caused by bacterial infections. Erythromycin hydrochloride is also involved in the inhibition of mammalian mRNA splicing. The application range of erythromycin hydrochloride includes respiratory tract infections, skin infections, and other infections caused by sensitive bacteria .
|
-
-
- HY-125546
-
|
Antibiotic
|
Infection
|
Erythromycin C is an antibiotic. Erythromycin C could be isolated from the fermentation process of the penicillium Streptomyces erythreus .
|
-
-
- HY-B0220S2
-
|
Bacterial
DNA/RNA Synthesis
Antibiotic
|
Infection
|
Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].
|
-
-
- HY-B0957R
-
|
Bacterial
HIV
Autophagy
Antibiotic
|
Infection
|
Erythromycin Ethylsuccinate (Standard) is the analytical standard of Erythromycin Ethylsuccinate. This product is intended for research and analytical applications. Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
|
-
-
- HY-B0220S
-
|
Bacterial
Antibiotic
|
Infection
|
Erythromycin-d6 is the deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].
|
-
-
- HY-122207R
-
|
Antibiotic
|
Infection
|
Erythromycin A enol ether (Standard) is the analytical standard of Erythromycin A enol ether. This product is intended for research and analytical applications. Erythromycin A enol ether is an acidic degradation product of Erythromycin A (macrolide antibiotic) and has no antibacterial effect .
|
-
-
- HY-122207
-
|
Antibiotic
|
Infection
|
Erythromycin A enol ether is an acidic degradation product of Erythromycin A (macrolide antibiotic) and has no antibacterial effect .
|
-
-
- HY-B0220D
-
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin thiocyanate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin thiocyanate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin thiocyanate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220B
-
|
Antibiotic
Bacterial
|
Infection
Cancer
|
Erythromycin gluceptate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin gluceptate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin gluceptate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220C
-
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-108875
-
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin stearate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin stearate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin stearate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220A
-
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin lactobionate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin lactobionate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin lactobionate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220F
-
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin glutamate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin glutamate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin glutamate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220E
-
|
Bacterial
Antibiotic
DNA/RNA Synthesis
|
Infection
Cancer
|
Erythromycin A dihydrate is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin A dihydrate binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin A dihydrate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-B0220S1
-
|
Isotope-Labeled Compounds
Bacterial
Antibiotic
|
Infection
|
Erythromycin- 13C,d3 is the 13C- and deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].
|
-
-
- HY-B0220S3
-
|
Bacterial
|
Infection
|
Erythromycin- 13C2 is a macrolide antibiotic that can be used to treat respiratory infections, skin infections, and chlamydia infections .
|
-
-
- HY-B0957S
-
Erythromycin ethyl succinate-13C,d3; EES-13C,d3
|
Isotope-Labeled Compounds
Bacterial
HIV
Autophagy
Antibiotic
|
Infection
|
Erythromycin ethylsuccinate- 13C,d3 is the 13C- and deuterium labeled Erythromycin Ethylsuccinate. Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
|
-
-
- HY-105932
-
Erythromycin A 9-methoxime; Wy 48314
|
Bacterial
Antibiotic
|
Infection
|
Lexithromycin is an erythromycin A derivative, with antibacterial activity.
|
-
-
- HY-B0643
-
LY237216
|
Bacterial
Antibiotic
|
Infection
|
Dirithromycin (LY237216), a derivative of Erythromycin, is a potent and orally active semi-synthetic macrolide antibiotic. Dirithromycin is active against gram-positive bacteria, Legionella spp., Helicobacter pylori, and Chlamydia trachomatis .
|
-
-
- HY-105263
-
|
Motilin Receptor
|
Metabolic Disease
|
EM574 is a potent motilin receptor agonist in the human gastric antrum and rabbit gastrointestinal tract in vitro. EM574 is an erythromycin derivative .
|
-
-
- HY-B0643R
-
|
Bacterial
Antibiotic
|
Infection
|
Dirithromycin (Standard) is the analytical standard of Dirithromycin. This product is intended for research and analytical applications. Dirithromycin (LY237216), a derivative of Erythromycin, is a potent and orally active semi-synthetic macrolide antibiotic. Dirithromycin is active against gram-positive bacteria, Legionella spp., Helicobacter pylori, and Chlamydia trachomatis .
|
-
-
- HY-128459
-
|
Drug Metabolite
|
Others
|
N-Demethylerythromycin A is a metabolite of Erythromycin A. Erythromycin A is an antibiotic .
|
-
-
- HY-116010
-
|
Bacterial
Antibiotic
|
Infection
|
Oleandomycin is a macrolide antibiotic structurally closely related to Erythromycin. Oleandomycin is similar to Erythromycin with antimicrobial activity.
|
-
-
- HY-128459R
-
|
Drug Metabolite
|
Others
|
N-Demethylerythromycin A (Standard) is the analytical standard of N-Demethylerythromycin A. This product is intended for research and analytical applications. N-Demethylerythromycin A is a metabolite of Erythromycin A. Erythromycin A is an antibiotic .
|
-
-
- HY-116010R
-
|
Bacterial
Antibiotic
|
Infection
|
Oleandomycin (Standard) is the analytical standard of Oleandomycin. This product is intended for research and analytical applications. Oleandomycin is a macrolide antibiotic structurally closely related to Erythromycin. Oleandomycin is similar to Erythromycin with antimicrobial activity.
|
-
-
- HY-112057
-
LY267108
|
Drug Metabolite
|
Others
|
Pseudoerythromycin A enol ether (LY267108) is a degradation product of Erythromycin. Pseudoerythromycin A enol ether has no significant antimicrobial activity .
|
-
-
- HY-N7454
-
|
Antibiotic
Bacterial
|
Infection
|
Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
|
-
-
- HY-158241
-
|
Bacterial
|
Infection
|
GmhA-IN-1 (compound 17) is an inhibitor of GmhA with an IC50 value of 2.4 nM. GmhA-IN-1 enhances the activity of erythromycin and rifampicin on wild-type E. coli .
|
-
-
- HY-N7454R
-
|
Antibiotic
Bacterial
|
Infection
|
Anhydroerythromycin A (Standard) is the analytical standard of Anhydroerythromycin A. This product is intended for research and analytical applications. Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
|
-
-
- HY-B1358
-
|
Bacterial
Antibiotic
|
Infection
|
Lincomycin hydrochloride monohydrate is a narrow-spectrum antibiotic, has similar effects to erythromycin, which has a good effect on gram-positive coccus, mainly used to inhibit the synthesis of bacterial cell protein .
|
-
-
- HY-149809
-
|
Bacterial
|
Infection
|
AcrB-IN-1 (Compound H6) is a potent AcrB inhibitor. AcrB-IN-1 can be used for the reversal of bacterial multidrug resistance .
|
-
-
- HY-B1358R
-
|
Bacterial
Antibiotic
|
Infection
|
Lincomycin (hydrochloride monohydrate) (Standard) is the analytical standard of Lincomycin (hydrochloride monohydrate). This product is intended for research and analytical applications. Lincomycin hydrochloride monohydrate is a narrow-spectrum antibiotic, has similar effects to erythromycin, which has a good effect on gram-positive coccus, mainly used to inhibit the synthesis of bacterial cell protein .
|
-
-
- HY-117845
-
LL-E19085α
|
Others
|
Infection
|
Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.
|
-
-
- HY-P3078
-
|
Bacterial
Antibiotic
|
Infection
|
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
|
-
-
- HY-116863
-
|
Bacterial
|
Infection
|
KKL-40 is a small molecule inhibitor that targets the trans-transcription process and is effective against methicillin-sensitive and -resistant Staphylococcus aureus (S. aureus) as well as other Gram-positive pathogens including vancomycin-resistant Enterococcus faecium, Bacillus subtilis, and Streptococcus pyogenes. KKL-40 synergizes with the human antimicrobial peptide LL-37 to inhibit S. aureus, but does not synergize with other antibiotics such as daptomycin, kanamycin, or erythromycin. Trans-transcription is an extreme form of recoding, and KKL-40 inhibits trans-transcription but is nontoxic to HeLa cells .
|
-
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3078
-
|
Bacterial
Antibiotic
|
Infection
|
Amphomycin is a lipopeptide antibiotic that inhibits peptidoglycan synthesis and blocks cell wall development. Amphomycin exhibits potent antibacterial activities against methicillin-resistant S. aureus (MRSA), vancomycin-resistant enterococci (VRE), penicillin-gentamicin-erythromycin-resistant S. pneumonia, and linezolid-quinupristin-dalfopristin-resistant enterococci .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0220
-
-
-
- HY-N7121
-
-
-
- HY-B0957
-
-
-
- HY-B0220D
-
-
-
- HY-B1358
-
-
-
- HY-125546
-
-
-
- HY-B0957R
-
-
-
- HY-B0220C
-
|
Classification of Application Fields
Disease Research Fields
Cancer
|
Antibiotic
Bacterial
DNA/RNA Synthesis
|
Erythromycin aspartate is a macrolide antibiotic produced by actinomycete?Streptomyces erythreus?with a broad spectrum of antimicrobial activity. Erythromycin aspartate binds to bacterial 50S ribosomal subunits and inhibits?RNA-dependent protein synthesis?by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid [1][2]. Erythromycin aspartate also exhibits antitumor and neuroprotective effect in different fields of research [3][4].
|
-
-
- HY-N7454
-
-
-
- HY-N7454R
-
|
Structural Classification
Macrolide Antibiotics
Antibiotics
Source classification
Antibacterial
Disease Research
Endogenous metabolite
|
Antibiotic
Bacterial
|
Anhydroerythromycin A (Standard) is the analytical standard of Anhydroerythromycin A. This product is intended for research and analytical applications. Anhydroerythromycin A is a degradation product of the macrolide antibiotic erythromycin. Anhydroerythromycin A is formed via degradation of erythromycin in acidic aqueous solutions in vitro as well as in vivo. Anhydroerythromycin A is active against S. aureus and B. cereus in vitro (MICs = 12.5 and 6.25 μg/ml, respectively). Anhydroerythromycin A also inhibits steroid 6β-hydroxylase activity associated with the cytochrome P450 (CYP) isoform CYP3A in human liver microsomes.
|
-
-
- HY-B1358R
-
-
-
- HY-117845
-
LL-E19085α
|
Structural Classification
Microorganisms
Antibiotics
Source classification
|
Others
|
Citreamicin alpha (LL-E 19085-alpha) is an antibiotic whose in vitro antimicrobial activity against 429 clinical isolates of Gram-positive cocci has been tested by the agar dilution method. These microorganisms included 313 strains of Staphylococci and 116 strains of Streptococci. The in vitro activity of Citreamicin alpha was compared with that of ampicillin, amoxicillin, ceftriaxone, erythromycin, and vancomycin. For Staphylococci, the MIC values of Citreamicin alpha ranged from 0.12-4.0 μg/ml, and for Streptococcus pyogenes of the genus Streptococcus, it was 0.03-0.12 μg/ml. However, enterococci were relatively resistant, requiring 2.0 μg/ml of the agent to inhibit 64% of the 62 tested strains. The in vitro activity of this antibiotic was much better than that of ampicillin, amoxicillin, ceftriaxone, and erythromycin, but comparable or slightly inferior to that of vancomycin.
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0220S2
-
|
Erythromycin-d3 is the deuterium labeled Erythromycin[1]. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin binds to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid. Erythromycin also exhibits antitumor and neuroprotective effect in different fields of research[2][3][4][5].
|
-
-
- HY-B0220S
-
|
Erythromycin-d6 is the deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].
|
-
-
- HY-B0220S1
-
|
Erythromycin- 13C,d3 is the 13C- and deuterium labeled Erythromycin. Erythromycin is a macrolide antibiotic produced by actinomycete Streptomyces erythreus with a broad spectrum of antimicrobial activity. Erythromycin acts by binding to bacterial 50S ribosomal subunits and inhibits RNA-dependent protein synthesis by blockage of transpeptidation and/or translocation reactions, without affecting synthesis of nucleic acid[1].
|
-
-
- HY-B0220S3
-
|
Erythromycin- 13C2 is a macrolide antibiotic that can be used to treat respiratory infections, skin infections, and chlamydia infections .
|
-
-
- HY-B0957S
-
|
Erythromycin ethylsuccinate- 13C,d3 is the 13C- and deuterium labeled Erythromycin Ethylsuccinate. Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: